Comparison and applicability of molecular classifications for gastric cancer.

O Serra, M Galán, M M Ginesta, M Calvo, N Sala, R Salazar

Journal: Cancer treatment reviews 2019;77():29-34

PMID: 31195213

Full Text on Elsevier Science View on PubMed

Abstract

Gastric Cancer (GC) is a complex and heterogeneous disease, which represents a global health concern. Despite advances in prevention, diagnosis, and therapy, GC is still a leading cause of cancer-related death. Over the last decade, several clinical trials have tested novel agents for advanced GC with mostly disappointing results. Heterogeneity, the absence of molecular selection in clinical trials and powerless predictive biomarkers may be potential explanations. Different molecular classification proposals for GC based on the genetic, epigenetic, and molecular signatures have been published. Molecular characterization of GC may offer new tools for more effective therapeutic strategies, such as the development of therapies for specifically well-defined sets of patients as well as the use of new clinical trial designs, which will ultimately lead to an improvement of medical management of this disease. However, the possibilities of implementation of GC molecular classifications on daily practice and their therapeutic implications remain challenging to date. In this review, we will describe and compare these GC molecular classifications, focusing on their main characteristics as the basis for their potential therapeutic implications and strategies for their clinical application. Key Message: A better understanding of gastric cancer molecular characteristics may lead to further improvements in treatment and outcomes for patients with the disease.

Address: Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) - University of Barcelona, Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Gastroesophageal Tumors Functional Unit (UTEG), Catalan Institute of Oncology (ICO) - Hospital Universitari de Bellvitge (HUB), Hospitalet de Llobregat, Barcelona, Spain. Electronic address: [email protected].; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) - University of Barcelona, Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Gastroesophageal Tumors Functional Unit (UTEG), Catalan Institute of Oncology (ICO) - Hospital Universitari de Bellvitge (HUB), Hospitalet de Llobregat, Barcelona, Spain.; Translational Research Laboratory, Catalan Insitute of Oncology (ICO), Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) - University of Barcelona, Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; CIBERONC Centro de Investigación Biomédica en Red Cáncer, Spain.; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) - University of Barcelona, Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Gastroesophageal Tumors Functional Unit (UTEG), Catalan Institute of Oncology (ICO) - Hospital Universitari de Bellvitge (HUB), Hospitalet de Llobregat, Barcelona, Spain.; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program and Translational Research Laboratory, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) - University of Barcelona, Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain; CIBERONC Centro de Investigación Biomédica en Red Cáncer, Spain.

DOI: 10.1016/j.ctrv.2019.05.005

Link outs

Free resources

Medical:

https://medlineplus.gov/stomachcancer.html

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3321

Subscription / membership required

Full Text Sources:

MeSH Terms: Genomic Instability, Humans, Neoplasm Staging, RNA, Messenger, Stomach Neoplasms